Beta-glucan (BDG) (BDG)

Beta-glucan polymers are complex polysaccharides composed of D-glucose monomers linked by beta-glycosidic bonds, serving as essential structural components in the cell walls of fungi, yeast, bacteria, and certain plants [1][2]. In clinical medicine, these polymers are primarily recognized as Pathogen-Associated Molecular Patterns (PAMPs) that trigger innate immune responses by binding to specific pattern recognition receptors, most notably Dectin-1 (CLEC7A) and Complement Receptor 3 (CR3) [3][4]. This interaction promotes the activation of macrophages, neutrophils, and natural killer cells, making beta-glucans a subject of interest as biological response modifiers in cancer immunotherapy and infectious disease management [5]. From a pharmacological perspective, the beta-glucan polymer is the functional target of the echinocandin class of antifungal drugs, such as caspofungin and micafungin [6]. These agents work by inhibiting the enzyme (1,3)-beta-D-glucan synthase, which prevents the formation of the polymer, leading to osmotic instability and lysis of the fungal cell [7]. Furthermore, the detection of (1,3)-beta-D-glucan in human serum serves as a vital diagnostic biomarker for invasive fungal infections, such as candidiasis and aspergillosis [8]. Despite their therapeutic potential, challenges include the risk of false-positive diagnostic tests caused by cross-reactivity with cellulose-based medical materials and the potential for infusion-related inflammatory reactions [9][10].

Other names

(1,3)-beta-D-glucan(1,6)-beta-D-glucanBeta-D-glucanBDGZymosanLentinanPleuranSchizophyllanLaminarin

Inhibition of (1,3)-beta-D-glucan synthase; Activation of Dectin-1 and Complement Receptor 3 (CR3) signaling.